Innovation

Have you ever wondered why cell therapies remain so expensive and hard to bring to patients worldwide, despite incredible scientific advances?

Dr. David Brühlmann

CMC Strategist

Innovation

Have you ever wondered why cell therapies remain so expensive and hard to bring to patients worldwide, despite incredible scientific advances?

Dr. David Brühlmann

CMC Strategist

Innovation

Have you ever wondered why cell therapies remain so expensive and hard to bring to patients worldwide, despite incredible scientific advances?

Dr. David Brühlmann

CMC Strategist

CMC and Bioprocess Blog

Execution-focused articles on CMC strategy, bioprocess scale-up, tech transfer, CDMO selection, and GMP readiness for process development scientists and manufacturing leaders scaling biologics into regulatory-ready therapies.

Biotech Success

How do you know when your biotech startup is ready to sell—before the product is “perfect”?

Biotech Success

Most bioprocess innovation is dismissed as a “fool’s game”—until the skeptics are proven wrong.

Innovation

Biotech startups face a labyrinth of decisions when it comes to manufacturing strategy.

Innovation

What if batch-to-batch variability was no longer just “part of the job” in tissue engineering and in vitro biology?

Bioprocessing

Is your next blockbuster biologic doomed before your team even steps into a lab?

Bioprocessing

What if your blockbuster biologic stumbled—not because the science wasn’t there, but because no one asked if it could actually be manufactured at scale?

Bioprocessing

What if the biggest advancement in bioprocessing isn’t a new AI algorithm or cutting-edge bioreactor, but a renewed focus on the foundational skills that drive innovation—and a clear-eyed look at what AI can (and can’t) really do for the industry right now?

Bioprocessing

How do you bridge the gap between cutting-edge industrial bioprocessing and the academic world tasked with training the next generation?

Bioprocessing

Today we’re talking about one of the most frustrating bottlenecks in biosimilar development: how to screen efficiently a long list of quality-modulating compounds when your standard tools

Bioprocessing

Today we’re talking about one of the most frustrating bottlenecks in biosimilar development: how to screen efficiently a long list of quality-modulating compounds when your standard tool

Bioprocessing

Getting an NDA signed shouldn’t feel like waiting for FDA approval. If your CRO needs weeks just to kickstart paperwork…

Bioprocessing

When drug safety fails, patients—and entire markets—pay the price. Understanding your CMC isn’t just compliance; it’s the line between therapeutic promise and product recall.

Data & Analytics

What does it take to crack the code of protein production—and why do some proteins stubbornly refuse to cooperate, despite the best efforts of scientists and engineers?

Data & Analytics

Somewhere in your lab, a hard drive is quietly storing omics data that hasn’t seen the light of day in years—genome sequences, metabolomics runs, scribbled notes in aging ELNs.

Data & Analytics

Leveraging digital models and AI-powered tools can make all the difference for both R&D and manufacturing, but finding the right starting point—and justifying the investment—can feel overwhelming.

Data & Analytics

Is your bioprocess development stacked with siloed data, endless spreadsheets, and a constant battle to identify where to start your digital transformation?

Data & Analytics

What separates labs with truly connected, AI-ready data from those drowning in digital chaos?

Data & Analytics

What if the real bottleneck in biotech labs isn’t equipment, talent, or even funding—but a silent issue lurking in plain sight: fragmented data?

Biotech Success

How do you know when your biotech startup is ready to sell—before the product is “perfect”?

Biotech Success

Most bioprocess innovation is dismissed as a “fool’s game”—until the skeptics are proven wrong.

Biotech Success

What happens when the solution to America’s insulin crisis isn’t a new molecule or fancy delivery device—but a new way of thinking about biotech itself?

Biotech Success

What if affordable insulin isn’t a scientific hurdle—but a financial and distribution puzzle no one’s been motivated to solve?

Biotech Success

Securing capital for biotech innovation has never been more challenging—or more crucial.

Biotech Success

Strong science alone won’t get your biotech startup funded—investors are sizing up much more than just your molecule.

Innovation

For decades, contract development and manufacturing organizations (CDMOs) have grown by building bigger stainless-steel facilities and squeezing ever-tighter margins.

Innovation

What if continuous microbial manufacturing wasn’t a pipe dream, but a reality quietly reshaping the foundations of bioprocessing?

Innovation

Imagine medicines grown like crops, ready for harvest in days, not months.

Innovation

But what if you could grow life-saving antibodies in a greenhouse instead?

Innovation

If biotech had a “cheat code” for sustainable manufacturing, what would it look like?

Innovation

What if the ocean’s tiniest inhabitants held the secret to decarbonizing the entire chemicals industry?

Enjoying what you're reading? Get the next deep-dive and digest in your inbox.

The Bioprocess Brief — biweekly digests, deep-dives, and field notes on biologics, cell and gene therapies, and AI-driven bioprocessing, written by a CMC practitioner.

No spam. Unsubscribe anytime.

Enjoying what you're reading? Get the next deep-dive and digest in your inbox.

The Bioprocess Brief — biweekly digests, deep-dives, and field notes on biologics, cell and gene therapies, and AI-driven bioprocessing, written by a CMC practitioner.


No spam. Unsubscribe anytime.